Signum Biosciences

MONMOUTH JUNCTION, NJ 08852

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $8.63MM
First Award Date 07/01/08
Most Recent Award Date 02/14/17

Key Personnel

Last Name Name Awards Contact
Braithwaite Steven P. Braithwaite 1
Gordon Joel S. Gordon 4
Shroot Braham Shroot 5
Perez Eduardo Perez 2

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 02/14/17 - 01/31/18

SUMMARY Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is needed. Although disease etiology has yet to be fully under...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is needed. Although disease etiol...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/20/13 - 08/31/14

DESCRIPTION (provided by applicant): Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is needed. Although disease etiol...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/13 - 07/31/14

DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease etiology remains unclear, skin inflammation has been identified as the main contributor to disease pathology. Isoprenylcysteine (IPC) analogs represen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease etiology remains unclear, skin inflammation has been identified as the main contributor to disease pathology. Isoprenylcysteine (IPC) analogs represen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/11 - 07/31/12

DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease etiology remains unclear, skin inflammation has been identified as the main contributor to disease pathology. Isoprenylcysteine (IPC) analogs represen...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Acne is a multifactorial disease affecting ~50 million people in the US. Three main factors contribute to the pathogenesis of acne;1) P. acnes growth 2) P. acnes-induced inflammation and 3) overproduction of sebum, all targets for therapeutic intervention. Treatments, such as antibiotics and benzylperoxide...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/15/10 - 07/31/12

DESCRIPTION (provided by applicant): Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau kinases (e.g. GSK-3, MAPK, cdk5, CK-1, PKA, CaMKII) are hindered by multiple and redundant tau phosphorylation pathways. In contrast, protein phospha...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/01/10 - 07/31/11

DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs modulate heterotrimeric G-protein coupled receptor (GPCR) signaling pathways, representing a novel class of topical anti-inflammatory compounds whose action is restricted to the site of application. Studies performed in the Phase I proposal demonstrate that IPC analogs have a w...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 07/01/10 - 06/30/12

DESCRIPTION (provided by applicant): N-acetyl-S-famesyl-L-cysteine (AFC) and its derivatives (isoprenylcysteine (IPC) analogs) represent a novel class of topically absorbed NSAIDs whose activity is restricted to the site of application with no detectable systemic effects and no adverse affects such as skin atrophy or inhibition of wound healing....

Load More